🇺🇸 FDA

Company profile · Sponsor

XBiotech

XBiotech Germany GmbH

XBIT · NYSE biotech AUSTIN, TX, EU
Pipeline
8
Drugs
1
Patents
8

Quick answer

XBiotech (XBIT) is a biotech company. headquartered in AUSTIN, TX, EU. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker XBIT
Exchange NYSE
Company type biotech
Headquarters AUSTIN, TX, EU
SEC CIK 0001626878

Pipeline (8)

Search pipeline →

  1. 514G3 (2 mg/kg) plus standard IV antibiotic treatment

    XBiotech

    Staphylococcus Aureus Bacteremia

    phase 2 mab completed

    1 trial

  2. Natrunix

    XBiotech

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  3. Natrunix 400 mg

    XBiotech

    Rheumatoid Arthritis

    phase 2 mab active

    1 trial

  4. Natrunix with MTX placebo (+folate)

    XBiotech

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  5. XB2001 or Placebo

    XBiotech

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  6. vilamakitug

    XBiotech

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  7. Hutrukin

    XBiotech

    Pharmacokinetics

    phase 1 mab completed

    1 trial

  8. NatrunixTM

    XBiotech

    Pharmacokinetics

    phase 1 mab active

    1 trial

Drugs (1)

Search drugs →

  1. human igg1 monoclonal antibody specific for human interleukin-1 alpha

    HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH

    L01

Patents (8)

Search patents →

  1. US 12116405

    Arthritis treatment

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11932688

    Treatment for neoplastic diseases

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11773157

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11529298

    Cosmetic composition and its use, dermocosmetic formulation

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11523981

    Cosmetic composition and its use, dermocosmetic formulation

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11370831

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10577410

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10294296

    Treatment for neoplastic diseases

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is XBiotech?

XBiotech (XBIT) is a biotech company. headquartered in AUSTIN, TX, EU. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does XBiotech sponsor?

We track 8 ClinicalTrials.gov-linked programs for XBiotech, including 514G3 (2 mg/kg) plus standard IV antibiotic treatment and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does XBiotech company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.